AbbVie's c-Met ADC wins dual FDA Breakthrough Therapy tags in CRC and lung cancer

AbbVie said on 7 October 2026 that the US Food and Drug Administration granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A; ABBV-400), a c-Met-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, one in colorectal cancer and one in non-small cell lung cancer ^[1].

Breakthrough Therapy Designation speeds development and review; it is not an approval. The FDA grants it when early evidence suggests a drug may offer substantial improvement over available therapy on a clinically significant endpoint, and the practical effect is more intensive agency guidance plus eligibility for rolling review once a marketing application is filed. Two designations in two separate solid tumors tell competitors that AbbVie's clinical data in each setting cleared that bar and that the agency is prepared to engage quickly when a filing arrives.

Colorectal is the program with a registrational spine

In colorectal cancer the designation sits on top of an active late-stage program. AbbVie is running a Phase 3 trial, NCT07525206, testing Temab-A plus bevacizumab against trifluridine/tipiracil plus bevacizumab in refractory metastatic disease, with a target of 990 patients; the study is recruiting ^[2]. A Phase 2 combination study, NCT06820463, pairs Temab-A with FOLFOX and either bevacizumab or panitumumab in metastatic colorectal cancer and targets 390 patients, also recruiting ^[3]. The comparator choice is the tell: AbbVie is positioning the ADC to displace trifluridine/tipiracil plus bevacizumab in the refractory setting, the regimen patients reach once earlier lines fail.

The lung signal is thinner in the public record

The non-small cell lung cancer designation is less visible in the trial record supplied here.

Timing: a designation that converts into no fixed date

Breakthrough status shortens FDA interaction and opens rolling and priority review, but it does not start a review clock. That clock begins only when AbbVie files a BLA. The dossier carries no filing date, no PDUFA target and no AbbVie statement on when an application will go in, so Prognyx cannot bound a decision window from these records. The Phase 3 colorectal trial is the catalyst that would support a filing, and it is still recruiting, which places any registrational readout well beyond the near term.

What Prognyx could not verify

The source for the designations is AbbVie's own press release; no independent FDA notice and no AbbVie securities filing in this dossier confirms them. A separate AbbVie 8-K filed on 5 October 2026 addresses third-quarter acquired IPR&D and milestone expense guidance and makes no mention of the ADC or the designations ^[5]. No dedicated late-stage NSCLC trial of telisotuzumab adizutecan appears in the records reviewed, so the data behind the lung designation are not visible. The release provided here does not give the FDA decision date for either designation.

Prognyx's read: a credible development signal for a mid-stage asset, with no near-term regulatory catalyst to act on. Threat level is moderate for refractory colorectal incumbents, and the window to act is long, set by a Phase 3 that is still enrolling.